BSP:BIIB34 (USA)
Business Description
Biogen Inc
NAICS : 325412
SIC : 2834
225 Binney Street, Cambridge, MA, USA, 02142
Compare
Compare
Traded in other countries / regions
BIIB.Argentina
•
BIIB.Austria
•
BIIB34.Brazil
•
IDP.Germany
•
BIIB.Mexico
•
BIIB.Switzerland
•
0R1B.UK
•
BIIB.USA
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.64 | |||||
| Debt-to-EBITDA | 2.42 | |||||
| Interest Coverage | 10.96 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.27 | |||||
| Beneish M-Score | -2.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.9 | |||||
| 3-Year EBITDA Growth Rate | -16.7 | |||||
| 3-Year EPS without NRI Growth Rate | -21.6 | |||||
| 3-Year FCF Growth Rate | -4.7 | |||||
| 3-Year Book Growth Rate | 3.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 1.01 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -9.46 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.5 | |||||
| 9-Day RSI | 49.47 | |||||
| 14-Day RSI | 51.66 | |||||
| 6-1 Month Momentum % | 5.03 | |||||
| 12-1 Month Momentum % | -34.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.94 | |||||
| Quick Ratio | 1.68 | |||||
| Cash Ratio | 0.96 | |||||
| Days Inventory | 195.81 | |||||
| Days Sales Outstanding | 70.16 | |||||
| Days Payable | 67.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 9.3 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.34 | |||||
| Operating Margin % | 27.39 | |||||
| Net Margin % | 19.37 | |||||
| ROE % | 18.65 | |||||
| ROA % | 8.52 | |||||
| ROIC % | 11.18 | |||||
| ROC (Joel Greenblatt) % | 54.79 | |||||
| ROCE % | 12.88 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.67 | |||||
| Forward PE Ratio | 13.42 | |||||
| PE Ratio without NRI | 15.67 | |||||
| Shiller PE Ratio | 11.46 | |||||
| Price-to-Owner-Earnings | 14.22 | |||||
| PS Ratio | 3.05 | |||||
| PB Ratio | 2.69 | |||||
| Price-to-Tangible-Book | 7.88 | |||||
| Price-to-Free-Cash-Flow | 13.99 | |||||
| Price-to-Operating-Cash-Flow | 12.74 | |||||
| EV-to-EBIT | 13.43 | |||||
| EV-to-Forward-EBIT | 11.69 | |||||
| EV-to-EBITDA | 11.09 | |||||
| EV-to-Forward-EBITDA | 9.7 | |||||
| EV-to-Revenue | 3.26 | |||||
| EV-to-Forward-Revenue | 3.46 | |||||
| EV-to-FCF | 14.96 | |||||
| Price-to-Projected-FCF | 0.67 | |||||
| Price-to-Median-PS-Value | 0.58 | |||||
| Price-to-Graham-Number | 2.34 | |||||
| Earnings Yield (Greenblatt) % | 7.45 | |||||
| Forward Rate of Return (Yacktman) % | 4.45 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 55,797.428 | ||
| EPS (TTM) (R$) | 12.061 | ||
| Beta | -0.16 | ||
| Volatility % | 27.09 | ||
| 14-Day RSI | 51.66 | ||
| 14-Day ATR (R$) | 2.31046 | ||
| 20-Day SMA (R$) | 188.211 | ||
| 12-1 Month Momentum % | -34.5 | ||
| 52-Week Range (R$) | 157.76 - 313.69 | ||
| Shares Outstanding (Mil) | 874.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biogen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||